C3 BIOTECHNOLOGIES LIMITED
Significant control: Michael Hyde Smith (significant control), Professor Nigel Scrutton (25–50%)
From public filings as at 31 Aug 2026; may contain errors or be out of date. Verify at Companies House · Terms
Watch this company
Get an email when Companies House records a change for C3 Biotechnologies Limited: status, filings, accounts, officers or owners. Free.
Not live yet: alerts start by 15 December 2026. We store your email and this company number only, for these alerts. If alerts don’t launch, we tell you and delete your address. Privacy
What does C3 Biotechnologies Limited sell?
Registered activity: Research and experimental development on biotechnology (SIC 72110). We’re building product and service lists for UK companies. Get this one when it’s ready.
Summary
C3 BIOTECHNOLOGIES LIMITED is an active private limited company (company number 09620994) incorporated on 3 June 2015, registered in Lancaster. Its registered activity is research and experimental development on biotechnology (SIC 72110). Latest small accounts cover the period ending 30 September 2025, showing net assets of £406k and cash of £97k, with 11 employees on average. Net assets fell 8% on the prior period (£442k).
By net assets it sits in the top quarter of 2,418 comparable companies in the UK (median £1,000, upper quartile £92k).
Ownership and control
- Mr Michael Hyde Smith
- has significant influence or control
- Professor Nigel Scrutton
- owns 25–50% of shares
- holds 25–50% of voting rights
- can appoint or remove directors
- Professor Nigel Shaun Scrutton
- has significant influence or control
- Mr Michael Hyde Smith
- has significant influence or control
- Mr Michael Hyde Smith
- owns 75–100% of shares
- holds 75–100% of voting rights
- can appoint or remove directors
Persons with significant control hold 25% or more of shares or voting rights. Smaller shareholdings are only listed in confirmation-statement documents. Directors and secretaries: see the officers list at Companies House.
Key dates
- Incorporated
- 3 June 201511 yrs ago
- Next accounts due
- 30 June 2027in 246 days
- Confirmation statement due
- 17 June 2027in 233 days
Due dates are expected from Companies House filing rules; confirm on the official register before relying on them.
Activity
- SIC 72110
- Research and experimental development on biotechnology
- Accounts type
- Small
- Size band
- MicroCompanies Act thresholds
Financials
| Period end | Net assets | Cash | Debtors | Creditors <1y | Turnover | Profit | Employees |
|---|---|---|---|---|---|---|---|
| 30 September 2025 | £406k | £97k | £51k | — | — | — | 11 |
| 30 September 2024 | £442k | £160k | £87k | — | — | — | 7 |
Figures as filed in iXBRL accounts at Companies House. "—" means the line was not reported in that filing.
Filing and accounts signals
- Net assets above zeroNet assets £405,818 at 30 September 2025
- Cash at bank of £50,000 or moreCash £97,087
- Incorporated five or more years agoIncorporated 3 June 2015
Neutral facts read from the register and filed accounts, each with its evidence. They are not a rating, a prediction or advice, and may be incomplete or out of date. How each signal is derived.
Timeline
- Next accounts duein 246 days
- Confirmation statement duein 233 days
- Accounts period endNet assets £406k · small accounts
- Accounts period endNet assets £442k · small accounts
- Incorporated
Similar companies in Lancashire
- CHIRON SCIENTIFIC WRITING LIMITEDKendal · inc. Aug 2015
- NANOPORE SOLUTIONS LTDLancaster · inc. Feb 2016
- BIOTECH RESOURCES (NL) LTDPreston · inc. May 2014
- PHARMGENE LIMITEDWhitehills Business Park · inc. Apr 2014
- DRUG SAFETY LIMITEDColne · inc. Jan 2017
- BAILRIGG IMMUNODIAGNOSTICS LIMITEDLancaster · inc. Mar 2017
All companies incorporated on 3 June 2015 · in Jun 2015.
Reminders for C3 BIOTECHNOLOGIES LIMITED
Get an email before each filing deadline — accounts and confirmation statement — so nothing is late.